Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Cash from Operations (2019 - 2025)

Greenwich LifeSciences filings provide 6 years of Cash from Operations readings, the most recent being 2671239.0 for Q3 2025.

  • Quarterly Cash from Operations fell 3.38% to 2671239.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 8591002.0 through Sep 2025, down 13.51% year-over-year, with the annual reading at 7266543.0 for FY2024, 12.16% down from the prior year.
  • Cash from Operations hit 2671239.0 in Q3 2025 for Greenwich LifeSciences, down from 2233103.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 528270.0 in Q1 2021 and bottomed at 2671239.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 1630290.32, with a median of 1800623.0 recorded in 2023.
  • The largest annual shift saw Cash from Operations crashed 268.65% in 2022 before it increased 20.06% in 2023.
  • Greenwich LifeSciences' Cash from Operations stood at 2264320.0 in 2021, then increased by 4.16% to 2170061.0 in 2022, then increased by 0.73% to 2154195.0 in 2023, then increased by 14.02% to 1852206.0 in 2024, then crashed by 44.22% to 2671239.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Cash from Operations are 2671239.0 (Q3 2025), 2233103.0 (Q2 2025), and 1834454.0 (Q1 2025).